Trial Profile
A Phase IIa, Open-label Study of Two Doses of GLPG1837 in Subjects With Cystic Fibrosis and the S1251N Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs GLPG 1837 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms SAPHIRA 2
- Sponsors Galapagos NV
- 10 Oct 2016 Status changed from recruiting to completed.
- 17 Mar 2016 According to a Galapagos media release, the company started first dosing in patients with S1251N mutation in the SAPHIRA 2 study in Feb 2016.
- 18 Feb 2016 New trial record